| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Andy Duggan, Juliet Warner, Martin Knapp, Robert Kerwi. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. The British journal of psychiatry : the journal of mental science. vol 182. 2003-07-10. PMID:12777341. |
modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the uk. |
2003-07-10 |
2023-08-12 |
Not clear |
| Leslie R H Drew, Kathleen M Griffiths, Donna M Hodgso. A five year follow-up study of the use of clozapine in community practice. The Australian and New Zealand journal of psychiatry. vol 36. issue 6. 2003-06-25. PMID:12406120. |
to present information about the value of clozapine in treatment-resistant schizophrenia. |
2003-06-25 |
2023-08-12 |
Not clear |
| Eugene H Makela, William D Cutlip, James M Stevenson, Jason M Weimer, Ehab S Abdallah, Raja S Akhtar, Ahmed S Aboraya, Erdogan Gune. Branded versus generic clozapine for treatment of schizophrenia. The Annals of pharmacotherapy. vol 37. issue 3. 2003-06-20. PMID:12639161. |
branded versus generic clozapine for treatment of schizophrenia. |
2003-06-20 |
2023-08-12 |
Not clear |
| Alan I Green, Melinda S Salomon, Mark J Brenner, Kimberly Rawlin. Treatment of schizophrenia and comorbid substance use disorder. Current drug targets. CNS and neurological disorders. vol 1. issue 2. 2003-06-18. PMID:12769622. |
while the typical antipsychotics do not limit the comorbid substance use, and may actually worsen it, preliminary data suggest the novel antipsychotic clozapine may have the unusual ability to dramatically decrease alcohol and other substance use in patients with schizophrenia. |
2003-06-18 |
2023-08-12 |
Not clear |
| Staffan Hägg, Staffan Rosenius, Olav Spigse. Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. International clinical psychopharmacology. vol 18. issue 3. 2003-06-17. PMID:12702898. |
we describe three patients with schizophrenia who developed granulocytopenia or agranulocytosis during treatment with clozapine and who did not respond to other antipsychotics. |
2003-06-17 |
2023-08-12 |
Not clear |
| Jeffrey A Lieberman, Michael Phillips, Hongbin Gu, Scott Stroup, Peiyan Zhang, Lan Kong, Zhongfu Ji, Gary Koch, Robert M Hame. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 5. 2003-06-11. PMID:12700715. |
atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. |
2003-06-11 |
2023-08-12 |
human |
| Jeffrey A Lieberman, Michael Phillips, Hongbin Gu, Scott Stroup, Peiyan Zhang, Lan Kong, Zhongfu Ji, Gary Koch, Robert M Hame. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 5. 2003-06-11. PMID:12700715. |
this flexible-dose study examined efficacy and safety in a randomized, double-blind, 52-week trial, comparing chlorpromazine (cpz) and clozapine (clz) in treatment naive patients experiencing their first episode of schizophrenia. |
2003-06-11 |
2023-08-12 |
human |
| Naoe Okamura, Kenji Hashimoto, Nobuhisa Kanahara, Eiji Shimizu, Chikara Kumakiri, Naoya Komatsu, Masaomi Iy. Protective effect of the antipsychotic drug zotepine on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. European journal of pharmacology. vol 461. issue 2-3. 2003-05-23. PMID:12586203. |
an atypical antipsychotic drug, zotepine, which is pharmacologically and clinically related to clozapine, has unique therapeutic effects on patients with schizophrenia. |
2003-05-23 |
2023-08-12 |
rat |
| P Garlipp, O Rosenthal, H Haltenhof, W Machleid. The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. Journal of psychopharmacology (Oxford, England). vol 16. issue 4. 2003-05-19. PMID:12503844. |
the development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. |
2003-05-19 |
2023-08-12 |
Not clear |
| P Garlipp, O Rosenthal, H Haltenhof, W Machleid. The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. Journal of psychopharmacology (Oxford, England). vol 16. issue 4. 2003-05-19. PMID:12503844. |
clozapine, the first atypical antipsychotic, is indicated for the treatment of therapy-resistant schizophrenia. |
2003-05-19 |
2023-08-12 |
Not clear |
| Verner J Knott, Alain LaBelle, Barry Jones, Colleen Mahone. EEG coherence following acute and chronic clozapine in treatment-resistant schizophrenics. Experimental and clinical psychopharmacology. vol 10. issue 4. 2003-05-15. PMID:12498341. |
eeg coherence in slow (delta and theta) frequencies was assessed in 17 treatment-resistant people with schizophrenia at baseline, 2 hr after their first oral dose (25 mg) and after 6 weeks of clozapine treatment. |
2003-05-15 |
2023-08-12 |
human |
| Jean A Frazier, Louise Glassner Cohen, Leslie Jacobsen, Dale Grothe, James Flood, Ross J Baldessarini, Stephen Piscitelli, Grace S Kim, Judith L Rapopor. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. Journal of clinical psychopharmacology. vol 23. issue 1. 2003-05-07. PMID:12544379. |
clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. |
2003-05-07 |
2023-08-12 |
Not clear |
| Rajesh Narendran, Carolyn M Young, Cynthia A Pristach, Michele T Pato, Antoinette M Valenti, Alice R Fas. Efficacy of clozapine in the treatment of atypical antipsychotic refractory schizophrenia: a pilot study. Journal of clinical psychopharmacology. vol 23. issue 1. 2003-05-07. PMID:12544385. |
efficacy of clozapine in the treatment of atypical antipsychotic refractory schizophrenia: a pilot study. |
2003-05-07 |
2023-08-12 |
Not clear |
| Yuan-Hwa Chou, Christer Halldin, Lars Fard. Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology. vol 166. issue 3. 2003-05-07. PMID:12589516. |
the serotonin 5-hydroxytryptamine-1a (5-ht(1a)) receptor subtype has been suggested to play a role in the pathophysiology of schizophrenia and is one among several central neuroreceptors for which clozapine has moderate affinity in vitro. |
2003-05-07 |
2023-08-12 |
Not clear |
| Deanna L Kelly, Elizabeth A Gale, Robert R Conle. Clozapine treatment in patients with prior substance abuse. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 48. issue 2. 2003-05-01. PMID:12655909. |
this study examined outcomes following discharge on clozapine for treatment-resistant schizophrenia patients with and without diagnosed substance abuse histories. |
2003-05-01 |
2023-08-12 |
Not clear |
| C Barbui, A Danese, G Guaiana, L Mapelli, L Miele, E Monzani, M Percudan. Prescribing second-generation antipsychotics and the evolving standard of care in Italy. Pharmacopsychiatry. vol 35. issue 6. 2003-04-28. PMID:12518273. |
nearly 80 % of patients receiving clozapine had schizophrenia compared to less than 50 % of those receiving other second-generation antipsychotics. |
2003-04-28 |
2023-08-12 |
Not clear |
| Antona Wagstaff, Caroline Perr. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS drugs. vol 17. issue 4. 2003-04-28. PMID:12665398. |
clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. |
2003-04-28 |
2023-08-12 |
Not clear |
| Antona Wagstaff, Caroline Perr. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS drugs. vol 17. issue 4. 2003-04-28. PMID:12665398. |
clozapine (mean 274.2 mg/day; n = 490) had a greater preventive effect on suicidality among patients with schizophrenia or schizoaffective disorder at high risk for suicide than olanzapine (mean 16.6 mg/day; n = 490) in a randomised, rater-blinded, multicentre study (p < 0.05; a 22-24% improvement). |
2003-04-28 |
2023-08-12 |
Not clear |
| Alan I Green, Ellen S Burgess, Ree Dawson, Suzannah V Zimmet, Rael D Strou. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia research. vol 60. issue 1. 2003-04-24. PMID:12505141. |
alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. |
2003-04-24 |
2023-08-12 |
Not clear |
| Alan I Green, Ellen S Burgess, Ree Dawson, Suzannah V Zimmet, Rael D Strou. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia research. vol 60. issue 1. 2003-04-24. PMID:12505141. |
we describe a retrospective study of the effects of the novel antipsychotics risperidone (risp) and clozapine on alcohol and cannabis use in patients with schizophrenia or schizoaffective disorder and comorbid alcohol and/or cannabis use disorder. |
2003-04-24 |
2023-08-12 |
Not clear |